Reciprocal interactions between tumor and endothelial cells: Effects of selective vasopressin V2 receptor peptide agonists

Recent experimental evidence suggested that the synthetic peptide desmopressin (DDAVP) interferes tumor angiogenesis by inducing the formation of angiostatin. It is also known that DDAVP stimulates the endothelial release of von Willebrand factor, a key element in resistance to metastasis. Vasopressin V2 receptor agonists such as DDAVP seem to evoke dual angiostatic and antimetastatic effects, breaking cooperative interactions of tumor and endothelial cells during tumor progression.Fil: Garona, Juan. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB.

Repurposing has gained momentum globally and become an alternative avenue for drug discovery because of its better success rate, and reduced cost, time and issues related to safety than the conventional drug discovery process. Several drugs have already been successfully repurposed for other clinical conditions including drug resistant tuberculosis (DR-TB). Though TB can be cured completely with the use of currently available anti-tubercular drugs, emergence of drug resistant strains of Mycobacterium tuberculosis and the huge death toll globally, together necessitate urgently newer and effective drugs for TB. Therefore, we performed virtual screening of 1554 FDA approved drugs against murE, which is essential for peptidoglycan biosynthesis of M. tuberculosis. We used Glide and AutoDock Vina for virtual screening and applied rigid docking algorithm followed by induced fit docking algorithm in order to enhance the quality of the docking prediction and to prioritize drugs for repurposing. We found 17 drugs binding strongly with murE and three of them, namely, lymecycline, acarbose and desmopressin were consistently present within top 10 ranks by both Glide and AutoDock Vina in the induced fit docking algorithm, which strongly indicates that these three drugs are potential candidates for further studies towards repurposing for TB

Von Willebrand Disease

Von Willebrand Disease (VWD) is a blood clotting disorder characterized by low levels of the Von Willebrand Factor (VWF) in the blood. VWF is functions to bind platelets and promote clotting of the blood when vascular injury occurs. Therefore, VWD leads to decreased or impaired clotting. There are three main types and four subtypes of VWD (type 1, 2A, 2B, 2N, 2M, and 3). Each type of VWD increases in severity. VWD is diagnosed preliminarily through a personal and family history and physical examination. Upon indications toward the possibility of a bleeding disorder, an initial hemostasis evaluation is performed followed by an initial VWD assay. The most common treatment for VWD is the use of desmopressin to promote VWF secretion into the bloodstream. New research addresses VWF- related proteins such as SNAP23 and ADAMTS-13 as well as organ transplantation and their respective effects on VWD

The management of nocturnal enuresis in children

Introduction : Nocturnal enuresis is more prevalent in the male gender. Studies such as that by Butler & McKenna (2002) show how nocturnal enuresis is hereditary, with approximately 50% of the children affected if one parent has suffered from it. The main cause for nocturnal enuresis can be drinking late in the evening or not passing urine before going to sleep, resulting in excessive urine volume. A detailed history needs to be taken, eating and drinking habits should also be assessed, and any drinks or food that can increase the chances of bedwetting should be removed or reduced. Management: Management has to be adapted to the child and his/her family requirements. Prescribing the right medication and ensuring compliance is important but is only part of the management plan. Lifestyle changes should be advised. A very simple bedwetting vibrating alarm can be considered. If symptoms persist, pharmacological treatment should be prescribed together with the bedwetting alarm. Conclusion: Nocturnal enuresis is a common condition in a young child, however it requires a careful assessment and management in cooperation with the child’s parent or carer. Physicians need to be aware of when the child needs to be referred.peer-reviewe